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Sažetak 
 
Poznato je da su koncentracije kolesterola u lipoproteinu visoke gustoće (HDL) 
inverzno povezane s kardiovaskularnim rizikom. Farmakološki postupci s ciljem 
povećanja HDL-a, kojima bi se rizik smanjio, do sada nisu bili uspješni (inhibicija 
kolesterol ester transfer proteina; CETP). Nadalje, studije o HDL-u na pacijentima s 
dijabetesom, koronarnom arterijskom bolesti (CAD) te drugim upalnim bolestima 
povezanim s funkcionalnošću HDL-a dale su jasan dokaz da:  
a) koncentracija HDL-a nije pouzdan prediktor kardiovaskularnog rizika  
b) brojnost i veličina čestica HDL-a te 
c) funkcionalnost HDL-a snažni su i nezavisni prediktori kardiovaskularnog rizika i 
smrtnosti. 
Prijašnji i sadašnji eksperimenti s endotelnom lipazom (EL) jasno pokazuju da enzim 
svojom fosfolipaznom aktivnošću utječe na fosfolipide HDL-a. Primarno, na 
fosfatidillkolin (PC) čime dolazi do promjena u strukturi i funkcionalnosti HDL-a. Taj 
HDL nazvan je EL-HDL. EL- HDL je veličinom manji od kontrolnog HDL-a. Sadrži 
manje fosfatidilkolina ali više lizofosfatidilkolina (LPC). EL-HDL pokazuje slabiji 
afinitet vezanja za receptore (SR-BI; scavenger receptor class B type I ), smanjenu 
mogućnost posredovanja pri transportu kolesterola iz makrofaga (efflux), smanjenu 
količinu i aktivnost enzima paraoksonaza-1 (PON-1) te promijenjenu aktivnost 
endotelne dušik oksid sintetaze (e-NOS) koja utječe na vazodilataciju posredovanu 
dušikovim monoksidom (NO).  
Učinak endotelne lipaze na HDL remodeliranje proučavan je u in vitro modelu 
stanične kulture HepG2 stanica inficiranih adenovirusima za endotelnu lipazu (EL), 
kolesterol ester transfer protein (CETP) te lecitin-kolesterol-acil-transferazu (LCAT), 
uz pripadajuće kontrole, kako bismo dobili ekspresiju spomenutih enzima. Nakon 
inkubacije seruma zdravih dobrovoljaca s HepG2 stanicama uz odsutsvo/prisutstvo 
inhibitora CETP-a (torcetrapib) i LCAT-a (DTNB-a (5,5-ditiobis-2-nitrobenzoična 
kiselina)), HDL je izoliran iz svakog uzorka seruma. Uzorci HDL-a su promatrani s 
obzirom na veličinu i sastav (sveukupni kolesterol, trigliceridi, fosfolipidi, sadržaj 
PON1) te funkcionalnost (PON-1 aktivnost, eNOS inducibilnu aktivnost, kapacitet 
prijenosa kolesterola iz makrofaga). Metode korištene u eksperimentu su bazirane na 
radu sa staničnim kulturama, gel elektroforezi, Western blotu, dostupnim kitovima i 
metodama bojenja lipida i proteina.  
Cilj eksperimenta je bio ispitati učinak CETP inhibitora (torcetrapiba) i LCAT inhibitora 
(DTNB-a) na veličinu, sastav i funkcionalnost EL-HDL-a.  
Rezultati pokazuju da je EL-HDL dobar supstrat za oba enzima – CETP, LCAT. 
Modulacija enzimima i inhibitori utječu na lipidni sastav EL-HDL-a, dok je veličina 
ostala ista, ali i dalje manja od kontrolnog HDL-a. Funkcionalnost EL-HDL-a je uvijek 
smanjena u usporedbi s kontrolnim HDL-om. Zaključno, farmakološkom modulacijom 
in vitro nije došlo do poboljšanja, spoznato narušenih kardioprotektivnih mehanizama 
EL-HDL-a u usporedbi s kontrolnim HDL-om.  
 
 
 
Summary 
 
It is well established that HDL concentrations in plasma estimated by measuring 
cholesterol in HDL (HDL-cholesterol in clinical laboratory results, HDL-C = good 
cholesterol) is inversely related to cardiovascular risk. However, the failure of recent 
pharmacological attempts (inhibition of cholesterol ester transfer protein; CETP) to 
decrease cardiovascular events by increasing HDL-C levels, together with additional 
studies showing that HDL from patients with various pathologies (diabetes, CAD, 
inflammation) is dysfunctional, provided clear evidence that:  
 
a) HDL-C levels are not reliable predictors of cardiovascular risk  
b) HDL particle number and size as well as  
c) HDL- functionality are strong and independent predictors of cardiovascular events 
and mortality.  
 
Previous and current work clearly demonstrated that EL (endothelial lipase) by its 
phospholipase activity very potently cleaves HDL phospholipids, primarily 
phosphatidylcholine (PC), thereby generating structurally and functionally altered 
HDL, referred to as EL-HDL. EL-HDL is smaller in size, depleted in PC but enriched 
in lysophosphatidylcholine (LPC). It exhibits diminished binding to SR-BI (scavenger 
receptor class B type I), a reduced capacity to mediate cholesterol efflux from 
macrophages, decreased paraoxonase 1 (PON1)-content and altered capacity to 
induce endothelial NO (nitric oxide) production and to promote vasorelaxation. 
  
 
Generation of modified HDL was achieved by incubation of healthy human pool 
serum with HepG2 cells transduced with adenoviruses encoding EL, CETP or LCAT. 
After isolation of modified HDL from serum (without and with inhibitors, after 
overexpression) following steps and methods were performed:  
- Structural/compositional analysis of HDL (native gradient electrophoresis followed 
by Sudan staining and Coomassie staining, lipid composition analysis using kit 
measurements, PON1 Western Blots).  
- Functionality assessment of HDL (HDL-associated PON1-activity, capacity of HDL 
to induce endothelial e-NOS activity and HDL cholesterol efflux capacity).  
 
The aim was to examine the impact of CETP inhibitor – torcetrapib and LCAT 
inhibitor -DTNB, on EL-induced alterations in structural and functional properties of 
HDL. 
Results showed that EL-modified HDL is a good substrate for CETP and LCAT. In 
vitro, both Torcetrapib and DTNB affected EL-HDL composition with no effect on the 
EL-HDL size. Furthermore, functionality of EL-HDL was decreased when compared 
to control HDL. In vitro pharmacological inhibition of CETP or LCAT activity failed to 
affect the impact of these enzymes on the functionality of EL-HDL. 
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1. Introduction 
 
 
Atherosclerotic coronary artery disease (CAD) and its complications remain the 
leading cause of death in industrialized countries. In recent years, intensive lowering 
of low-density lipoprotein (LDL) cholesterol using statins has been established as an 
effective therapy to lower cardiovascular risk. However, the risk of major 
cardiovascular events in patients with CAD on optimal medical therapy, including 
statins, remains in the range of 20% after 3 years of follow-up after an acute coronary 
syndrome. Several lines of evidence have suggested that high-density lipoprotein 
(HDL) may act as an anti-atherogenic lipoprotein. HDL-targeted therapies are 
therefore intensely pursued as a potential novel anti-atherogenic strategy to reduce 
cardiovascular risk and are an important frontier of basic, translational and clinical 
cardiovascular research. Low high-density lipoprotein (HDL)-cholesterol levels are 
associated with an increased risk of coronary artery disease (CAD) and myocardial 
infarction, which has triggered the hypothesis that HDL, in contrast to low-density 
lipoprotein (LDL), acts as an anti-atherogenic lipoprotein. Moreover, experimental 
studies have identified potential anti-atherogenic properties of HDL, including 
promotion of macrophage cholesterol efflux and direct endothelial-protective effects 
of HDL, such as stimulation of endothelial nitric oxide production and repair, anti-
apoptotic, anti-inflammatory and anti-thrombotic properties. Studies in gene-targeted 
mice, however, have also indicated that increasing HDL-cholesterol plasma levels 
can either limit (e.g. ApoA1; apolipoprotein A-I) or accelerate (e.g. SR-BI; scavenger 
receptor class B type I) atherosclerosis. Moreover, vascular effects of HDL have 
been observed to be heterogenous and are altered in patients with CAD or diabetes - 
‘HDL dysfunction’ (1).  
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These alterations in biological functions of HDL may need to be taken into account 
for HDL-targeted therapies and considering raising of HDL-cholesterol levels alone is 
likely not sufficient in this respect. It will therefore be important to further determine, 
which biological functions of HDL are critical for its anti-atherosclerotic properties, as 
well as how these can be measured and targeted (1). Initially, the concept that HDL 
may protect from CAD was suggested by numerous epidemiological studies, 
indicating that low plasma levels of HDL cholesterol or apoA1, the major protein 
component of HDL, are associated with an increased risk of CAD and CAD-related 
cardiovascular events in the general population (2). Studies have suggested that also 
in patients with CAD and very low LDL cholesterol levels on statin treatment, low 
plasma concentrations of HDL cholesterol remained associated with an increased 
risk of cardiovascular events. Low HDL cholesterol levels have also been suggested 
as a primary lipid abnormality in patients with premature CAD. However, low plasma 
HDL cholesterol levels may not generally be associated with accelerated 
atherosclerosis (3).  
1.1. Biosynthesis of HDL 
The first step of the biosynthesis of HDL entails the synthesis and secretion of apoA-
I, the major protein constituent of HDL, by the liver and intestine. The second most 
abundant HDL protein, apoA-II, is synthesized only in the liver and its secretion 
results in the formation of a subclass of HDL particles containing apoA-I and apoA-II. 
Following secretion in the liver and intestine, lipid-poor apoA-I immediately acquires 
cholesterol and phospholipids, in particular from hepatocytes and enterocytes. The 
initial lipidation of apoA-I is primarily mediated by ABCA-1 (ATP-binding cassette 
transporter A-1) and results in the formation of nascent HDL. Nascent HDL acquires 
additional phospholipids and free cholesterol from extrahepatic tissues (1). 
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In addition, HDL acquires phospholipids and potentially apolipoproteins (such as 
apoC-III) during hydrolysis of triglyceride-rich lipoproteins. The transfer of 
phospholipid surface remnants from triglyceride-rich lipoproteins to HDL is mediated 
via the phospholipid transfer protein (PLTP). Phospholipids transferred via PLTP are 
not only an important structural component of the HDL surface, but also serve as 
substrate for the esterification of HDL-associated cholesterol. Moreover, PLTP 
promotes the fusion of smaller HDL3 particles and subsequent generation of larger 
HDL2 particles. During this process, lipid-poor apoA-I is shed off and can again 
undergo lipidation for regeneration of pre-beta-HDL. In transgenic animal models, 
increased systemic levels of PLTP have been shown to promote atherosclerosis in 
mice and rabbits. PLTP deficiency in atherosclerosis-prone mice results in decreased 
atherosclerotic plaque formation. These findings have been attributed, at least in 
part, to changes in apolipoprotein B (apoB) production and plasma cholesterol levels 
in these animals, since PLTP also stimulates hepatic secretion of VLDL (very low-
density lipoprotein), possibly by phospholipidation of nascent apoB (1).  
Following efflux of cholesterol and phospholipid transfer from peripheral tissues, a 
proportion of HDL-associated free cholesterol in plasma is esterified to cholesteryl 
ester by lecithin–cholesterol acyltransferase (LCAT). Although LCAT activity results 
in the formation of a hydrophobic core in HDL and thus is important for maturation of 
the HDL particle, recent studies in subjects with LCAT mutations and LCAT-
transgenic mice have suggested that LCAT likely does not play a major role for 
efficient transport of cholesterol from peripheral tissues back to the liver. As 
described above, the findings with respect to the vascular phenotype of subjects with 
LCAT mutations are heterogenous (1). 
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Hepatic SR-BI (scavenger receptor class B type I) can selectively take up cholesteryl 
ester and unesterified cholesterol and thus directly deliver HDL-associated 
cholesterol to the liver. Alternatively, in humans and some other species, HDL 
cholesterol can be transferred to apoB-containing lipoproteins in exchange for 
triglycerides via the cholesteryl ester transfer protein (CETP) and subsequently be 
cleared by LDL receptor-mediated uptake of apoB-containing lipoproteins to the liver. 
In transgenic mice (that normally lack CETP) with CETP gene transfer, the transport 
of cholesterol from macrophages to the liver was increased. However, studies on the 
effect of CETP on development of atherosclerosis in mice have yielded mixed 
results. Whereas overexpression of CETP increased atherosclerosis in wild-type and 
hypercholesterolemic mouse, a decreased atherosclerotic plaque burden was 
observed in CETP transgenic hypertriglyceridemic mice and in CETP transgenic 
mice overexpressing LCAT, despite lower plasma HDL cholesterol levels in these 
animals. In rabbits (that are expressing CETP), inhibition of CETP by JTT-705 
(known as dalcetrapib) attenuated atherosclerosis. Because CETP inhibition may 
change the composition of HDL particles and give rise to large HDL particles 
enriched in cholesterol esters, another study sought to characterize the ability of HDL 
from CETP-deficient subjects to mediate cholesterol efflux from macrophage foam 
cells. However, the cholesterol efflux potential of HDL isolated from human subjects 
with homozygous CETP deficiency was rather increased compared to 
normolipidemic control subjects. Importantly, whether pharmacological CETP 
inhibition by different CETP inhibitors affects other antiatherogenic properties of HDL 
in patients with CAD remains to be tested in future studies (1). 
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1.2. Molecular mechanisms mediating potential atheroprotective functions of 
HDL: alterations in cardiovascular disease 
In recent years, several properties or functions of HDL have been identified that 
could exert anti-atherosclerotic effects. Besides promoting macrophage cholesterol 
efflux and RCT (reverse cholesterol transport), HDL has more recently been shown 
to exert direct potentially antiatherosclerotic effects on endothelial cells, such as the 
direct stimulation of endothelial nitric oxide production by HDL or endothelial anti-
inflammatory effects and anti-oxidant effects. Recent evidence suggests that 
vascular effects of HDL are altered in patients with cardiovascular disease (1). 
In recent years, it has become clear that HDL from healthy subjects can exert direct 
potential atheroprotective effects on endothelial cells and the understanding of the 
vascular effects of HDL considerably changed with the important observation that 
HDL may directly stimulate endothelial NO synthase (eNOS) mediated NO (nitric 
oxide) production as well as induce endothelium dependent, NO-mediated 
vasodilation via endothelial SR-BI (Fig.1) (4). Endothelial NO plays a crucial role in 
the regulation of vascular tone and structure and importantly, endothelial NO has 
been shown to exert a variety of atheroprotective effects in the vasculature, such as 
anti-thrombotic, anti-coagulant, anti-inflammatory and pro-fibrinolytic effects. In 
addition, experimental studies have consistently demonstrated the capacity of HDL to 
modify eNOS expression as well as activity and to stimulate endothelial NO 
production in vitro and in vivo. Several different mechanisms have been proposed to 
account for the endothelial NO-stimulating capacity of HDL (5). Early studies have 
suggested that HDL acts by preventing the detrimental effects of oxidized LDL on 
endothelial NO-synthase while a subsequent study by Yuhanna et al. suggested that 
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HDL can bind to endothelial SR-BI and thus directly stimulate eNOS-mediated NO 
production (6).  
Exact mechanism of molecular pathway that activates eNOS in endothelial cells 
stimulated with HDL remains to be further elucidated (1).  
1.3. Potential HDL-targeted therapies  
According to a recent classification the HDL targeting drugs that are currently tested 
in preclinical or clinical studies are divided into four groups: 
1) directly augmenting apoA-I levels (apoA-I infusions, up-regulators of endogenous apo A-I 
production),  
2) indirectly augmenting apoA-I and HDL cholesterol levels (CETP inhibitors, niacin, 
endothelial lipase inhibitors),  
3) mimicking the functionality of apoA-I (i.e. apoA-I mimetics),  
4) enhancing RCT (liver receptor agonists, LCAT activators).  
Most of these HDL-targeted drugs are still in preclinical or early clinical investigation being 
tested (7).  
 
CETP inhibitors 
The interest in pharmacological CETP inhibition as novel therapeutic approach to 
raise HDL cholesterol levels was kindled by the finding of elevated HDL cholesterol 
levels in Japanese families with genetic CETP deficiency. However, the first 
compound tested in large clinical trials, torcetrapib, did not to reduce the progression 
of carotid atherosclerosis in patients with familial hypercholesterolemia receiving 
statin treatment and was associated with progression of disease in the common 
carotid segment. Of note, these effects occurred despite a pronounced increase in 
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HDL cholesterol levels and a substantial decrease in LDL cholesterol and 
triglycerides (7). More importantly, in the Investigation of Lipid Level Management to 
Understand its Impact in Atherosclerotic Events (ILLUMINATE) study, a large clinical 
outcome trial characterizing the effects of torcetrapib on major cardiovascular events 
in patients at high cardiovascular risk who were receiving statins, torcetrapib therapy 
was associated with an increased risk of cardiovascular events and death from any 
cause. This was, at least in part, due to an increase in blood pressure, systemic 
aldosterone levels and alterations in serum electrolytes related to ‘off-target’ effects 
of the compound on aldosterone and cortisol synthesis in adrenal cortical cells (8). 
Moreover, torcetrapib administration to spontaneously hypertensive rats impairs 
endothelial NO production and increases production of reactive oxygen species as 
well as endothelin-1 in the endothelium, leading to endothelial dysfunction in these 
animals. Other CETP inhibitors were/are currently in clinical trials, i.e. dalcetrapib, 
anacetrapib and evacetrapib. In contrast to torcetrapib, none of these agents has 
been shown to alter blood pressure, electrolytes or serum aldosterone (9).  
 
1.4. Heterogenity of the HDL proteome and HDL lipidome 
Recent proteomics studies have identified between 28 and 67 HDL-associated 
proteins using liquid chromatography–electrospray ionization tandem mass 
spectrometry (LC-ESI-MS/MS) (10). Interestingly, these proteomics studies of HDL 
have found not only proteins with well-characterized roles in lipid metabolism and 
antioxidant properties of HDL, but also a number of proteins involved in the acute 
phase response, complement regulation and proteinase inhibition. Of note, the 
protein composition of HDL may differ between healthy subjects and patients with 
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CAD, suggesting a potential remodeling of the HDL particle in these patients. A 
combined statin and niacin therapy partially reversed changes in the HDL proteome 
observed in patients with CAD, yielding a protein composition that resembled that in 
apparently healthy age- and sex-matched control subjects. However, whether 
changes in the HDL proteome are of relevance for the altered vascular effects of 
HDL in patients with CAD needs to be examined in future studies. Posttranslational 
modifications of apoA-I have been shown to impair the cholesterol efflux capacity of 
HDL (Fig 1). In particular, myeloperoxidase (MPO), a hypochlorous acid (HOCl)-
generating enzyme that is enriched in human atheroma, can modify apoA-I and 
induce chloro- and nitrotyrosine formation as well as methionine oxidation. 
Modification of HDL by MPO leads to a profound impairment of the cholesterol efflux 
capacity of HDL and an impaired capacity of HDL to stimulate endothelial NO 
production. Besides MPO-mediated oxidation, modification of HDL by 
malondialdehyde, an advanced lipid oxidation product, has been shown to impair the 
cholesterol efflux capacity of HDL in vitro, suggesting that lipid oxidation itself can 
induce alterations of HDL-associated proteins (1).  
 Considerably less is known about the HDL lipidome. It has been demonstrated that 
HDL is enriched in phosphatidylcholine, lysophosphatidylcholine, phosphatidyl-
ethanolamine and phosphatidylethanolamine-based plasmalogens, when compared 
to other lipoprotein fractions in plasma (11). However, a comprehensive and detailed 
profiling of the molecular lipid species in HDL including information on the type of 
fatty acids and the position where they are attached to the glycerol backbone is not 
yet available. Furthermore, it remains unknown whether the HDL-associated lipid 
profile differs in patients with stable CAD or acute coronary syndrome. Interestingly, it 
has been demonstrated that the phosphatidylcholine species composition of HDL 
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influences its anti-inflammatory activity, suggesting that the lipid composition might 
be an important determinant of HDL functionality. However, this needs to be tested in 
more detail in future studies (1).  
 
1.5. Role of PON1 for lipid oxidation and impaired endothelial protective effects 
of HDL in patients with CAD  
PON1 (paraoxonase-1) is an HDL-associated esterase/lactonase that has been 
shown to protect against lipid peroxide formation in LDL and HDL. The activity of 
HDL-associated PON1 was profoundly impaired in HDL from patients with CAD as 
compared to HDL from age and gender-matched healthy subjects. Inhibition of HDL-
associated PON1, as observed in patients with CAD, led to an increase of MDA-
lysine adducts in HDL that subsequently activated endothelial protein kinase C beta II 
(PKCbII) via the endothelial LOX-1 receptor (lectin-like oxidized LDL receptor 1) 
(Fig.1) (12).  
An important open question in the field remains which alterations of the 
atheroprotective functions of HDL are related to adverse clinical cardiovascular 
outcome in CAD patients. It is presently unknown which potential atheroprotective 
function of HDL, or which particular protein or lipid marker in HDL, may be suited 
best to assess the antiatherogenic capacity of HDL. It seems likely that only raising 
HDL with vasoprotective properties can be expected to exert beneficial 
cardiovascular effects (1). 
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Figure 1. Alterations of the atheroprotective effects of HDL in patients with CAD.  
 
Modification of apoA-I by MPO has been shown to impair the macrophage cholesterol efflux capacity 
of HDL. More recently, accumulation of MDA in HDL from patients with CAD due to an impaired HDL-
associated PON1 activity has been observed to stimulate activation of endothelial PKCbeta-II via the 
LOX-1 receptor. PKCbeta-II activation by HDL from patients with CAD inhibited Akt-dependent 
phosphorylation of eNOS at serine residue 1177 and increased the inhibitory eNOS phosphorylation at 
threonine 495, leading to reduced endothelial NO production (1). 
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1.6. HDL remodeling 
Remodeling and catabolism of HDL is the result of interactions of HDL with cell 
receptors and other membrane and plasma proteins including hepatic lipase (HL), 
endothelial lipase (EL), phospholipid transfer protein (PLTP), cholesteryl ester 
transfer protein (CETP), apolipoprotein M (apoM), scavenger receptor class B type I 
(SR-BI), ATP-binding cassette transporter G1 (ABCG1), the F1 subunit of ATPase 
(Ecto F1-ATPase), and the cubulin/megalin receptor. Following synthesis by the liver 
and the intestine, HDL is remodeled by various plasma proteins and is subsequently 
catabolized in the plasma by cell receptors and other plasma proteins (Fig. 2.) (13).  
HDL remodeling affects the structure and metabolic turnover of HDL and generates a 
dynamic mixture of discrete HDL subfractions that vary in size, shape, apolipoprotein, 
and lipid composition and functions. Remodeling of HDL by the action of hepatic 
lipase (HL) and endothelial lipase (EL) involves hydrolysis of residual triglycerides 
and some phospholipids of HDL leads to the conversion of HDL2 to HDL3 and preβ-
HDL and accelerates the catabolism of HDL. Portion of the cholesteryl esters formed 
by the actions of LCAT can be transferred to VLDL/IDL/LDL by the cholesteryl ester 
transfer protein (CETP). The phospholipid transfer protein (PLTP) can transfer the 
phospholipids from VLDL/IDL to the HDL particle during lipolysis to generate HDL2 
and can also convert HDL3 particles to HDL2 and preβ-HDL. HDL-binding 
proteins/receptors or transporters have been documented at all steps of HDL 
metabolism and involve the SR-BI, which is mostly expressed in hepatocytes, 
macrophages, and steroidogenic tissues and mediates selective CE uptake by the 
cells and tissues and cholesterol efflux; the ABCG1, which mediates cholesterol 
efflux. HDL is first remodeled in the circulation and subsequently catabolized by cells 
and tissues. Hepatic lipase (HL) and endothelial lipase (EL) are two plasma lipases 
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playing an important role in HDL remodeling. HL and EL have specificity primarily for 
phospholipids and to a lesser extend for triglycerides of apoB containing lipoprotein 
remnants and large HDL. Recent study demonstrated that targeted inactivation of 
both HL and EL in mice promoted macrophage-to-feces RCT (reverse cholesterol 
transport) and enhanced HDL antioxidant properties. HL-deficient patients have 
elevated plasma concentrations of cholesterol in the HDL and β-VLDL and increased 
concentration of triglycerides and phospholipids in the LDL and HDL. Analyses 
carried out in complete and partial HL-deficient subjects as well as in 
normotriglyceridemic and hypertriglyceridemic controls suggested that HL activity is 
important for physiologically balanced HDL metabolism. However, the presence of 
HL may not be necessary for normal HDL-mediated reverse cholesterol transport 
process and is not associated with pro-atherogenic changes in HDL composition and 
metabolism (13). 
Endothelial lipase (EL) is an enzyme with phospholipase activity (mostly PLA1 
activity) with additional weak triglyceride lipase activity. Overexpression of EL in mice 
markedly decreased plasma HDL cholesterol and apoA-I levels, had a modest effect 
on apoB-containing lipoproteins, and increased 2.5–3-fold the uptake of the HDL by 
the kidney and the liver. In contrast, the EL deficiency in mice increased HDL 
cholesterol levels and reduced atherosclerosis in the background of apoE/mice. 
Overexpression of EL in mice markedly decreased plasma HDL cholesterol and 
apoA-I levels and had a modest effect on apoB-containing lipoproteins. Furthermore, 
the HDL phospholipid and cholesteryl ester content decreased, while HDL 
triglyceride content increased and the free cholesterol content remained unaltered. 
Fast protein liquid chromatography analysis and agarose gel electrophoresis showed 
that the expression of EL resulted in the generation of small preβ-HDL particles. Data 
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support a model in which EL-mediated phospholipid hydrolysis of HDL destabilizes 
the particle, resulting in the shedding of poorly lipidated apoA-I from the particle 
surface, which are preferentially cleared by the kidneys and via increased selective 
uptake by SR-BI. Several genetic EL variants have been reported to be associated 
with plasma HDL-C levels, and genome-wide association studies have shown that 
single-nucleotide polymorphisms (SNPs) are associated with plasma HDL-C levels. 
However, the relationship of genetic variation in the EL locus with the risk for 
coronary artery disease remains uncertain. A newer study showed that carriers of an 
EL mutant characterized by complete loss of function had significantly higher plasma 
HDL cholesterol levels compared to carriers having partial loss-of-function mutations 
(13). 
 
1.7. HDL cargo 
Along proteins, variety of lipids are also carried by HDL, and some of them are or can 
be transformed to potent bioactive molecules. Furthermore, HDL carries and 
transports fat soluble vitamins, steroid hormones, carotenoids, as well as numerous 
more polar metabolites such as heneicosanoic acid, pentitol, and oxalic acid which 
were found to be significantly correlated with insulin resistance. It has been reported 
that HDL also transports small RNAs, including microRNAs, tRNA-derived RNA 
fragments, and RNase P-derived RNA fragments. How all this protein and lipid 
decoration affects HDL metabolism and HDL particle function remain to be studied 
(14). 
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Figure 2. HDL remodeling. 
 Mature HDL3 and HDL2 are generated from lipid-free apoA-I or lipid-poor pre-β1-HDL as the 
precursors. These precursors are produced as nascent HDL by the liver or intestine or are released 
from lipolysed VLDL and chylomicrons or by interconversion of HDL3 and HDL2. ABC1-mediated lipid 
efflux from cells is important for initial lipidation; LCAT-mediated esterification of cholesterol generates 
spherical particles that continue to grow on ongoing cholesterol esterification and PLTP-mediated 
particle fusion and surface remnant transfer. Larger HDL2 particles are converted into smaller HDL3 
particles on CETP-mediated export of cholesteryl esters from HDL onto apoB-containing lipoproteins, 
on SR-BI–mediated selective uptake of cholesteryl esters into liver and steroidogenic organs, and on 
HL- and EL-mediated hydrolysis of phospholipids. HDL lipids are catabolized either separately from 
HDL proteins (by selective uptake or via CETP transfer) or together with HDL proteins (ie, via uptake 
through as-yet-unknown HDL receptors or apoE receptors). The conversion of HDL2 into HDL3 and 
the PLTP-mediated conversion of HDL3 into HDL2 liberated lipid-free or poorly lipidated apoA-I. A part 
of lipid-free apoA-I undergoes glomerular filtration in the kidney and tubular reabsorption through 
cubilin. Blue arrows represent lipid transfer processes, and red arrows represent protein transfer 
processes. TGRL indicates triglyceride-rich lipoproteins (14).  
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2. Objective 
 
Our previous and current work clearly demonstrated that EL by its phospholipase 
activity very potently cleaves HDL phospholipids, primarily phosphatidylcholine (PC), 
thereby generating structurally and functionally altered HDL, referred to as EL-HDL. 
EL-HDL is smaller in size, depleted in PC but enriched in lysophosphatidylcholine 
(LPC) and free fatty acids. It exhibits diminished binding to SR-BI, a reduced capacity 
to mediate cholesterol efflux from macrophages, decreased paraoxonase 1 (PON1)-
content and altered capacity to induce endothelial NO production and to promote 
vasorelaxation (15-19). 
In the present study, we aimed to examine the impact of CETP and LCAT as well as 
their inhibitors, torcetrapib and DTNB, respectively, on structural and functional 
properties of EL-HDL. 
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3. Methods and materials 
 
Sequential Modification of HDL:  
    1. Transduction of HepG2 cells with empty-adenovirus (EV) (1µL/mL) used as a 
control, and EL adenovirus (0.35 µL/mL). 
     2. Serum modification: Human pool-serum (50%; diluted 1:1 with cell culture 
medium) was incubated with EL-overexpressing cells or EV-control cells in the 
presence of 4% BSA (bovine serum albumin) for 16 h, followed by collection of 
serum. 
     3. Collected serum was incubated with EV-control or HepG2 cells transduced with 
adenovirus (3µL/mL) encoding CETP or LCAT enzymes without or with inhibitors in 
the presence of 4% BSA for 12 h, followed by collection of serum.  
     4. Isolation of HDL from serum modified with EL, CETP or LCAT, by 
ultracentrifugation. 
Structural/compositional analysis of modified HDL with 
     1. Native gradient (4-15%) gel electrophoresis followed by Sudan staining (neutral 
lipids): enables to see the alterations in HDL size. 
     2. Native gradient gel electrophoresis followed by PON1 Western blot: enables to 
see distribution of PON1 on HDL particles of various sizes. 
     3. Kit measurement for determination of lipid composition  
Functionality assessment of modified HDL by 
     1. HDL-associated PON1-activity measurement. 
     2. measurement of capacity to induce e-NOS-inducing activity. 
     3. measurement of cholesterol efflux capacity. 
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Serum modification and Cell culture   
Human serum was collected after overnight fasting from 10 healthy subjects (6 
females and 4 males). To obtain serum, blood was incubated for 30 min at room 
temperature (RT) followed by centrifugation (3000 x g) at 4°C for 15 min. Pooled 
serum was stored at -80°C or used immediately for further experiments in cell 
culture. 
 
All cell types were cultured in humidified atmosphere of 5% CO2/95% air at 37°C. 
HepG2 cells (ATCC®, HB-8065TM) were cultured in Dulbecco's modified Eagle 
medium (DMEM) containing 10% fetal bovine serum (FBS) (all Gibco, Life 
Technologies). Cell culture medium was supplemented with penicillin G sodium 
sulfate (100 units/ml), streptomycin sulfate (100 mg/ml), and amphotericin B (2.5 
mg/ml) (all Gibco, Life Technologies).  
HepG2 cells were plated onto 60 mm dishes. After 24 h, cells were washed once with 
DMEM without FCS and were infected, separately, with recombinant adenoviruses 
encoding human EL, CETP and LCAT in DMEM without FCS for 2 h. After removal of 
infection media cells were incubated with fresh DMEM containing 10% fetal calf 
serum (FCS) for 24 h. Afterwards, cells were washed once with DMEM without FCS, 
followed by incubation of 1.8 ml of 50 % pooled human serum in DMEM without FCS, 
with EV- or EL-transduced cells for 16 h. After incubation, the serum was collected 
and spun at 1100 x g for 3 min to remove cellular debris and further incubated with 
CETP- or LCAT-transduced cells in the absence or presence of respective inhibitors 
for further 12 h. HDL was isolated from modified serum by ultracentrifugation. 
Human endothelial cell line EA.hy926 (ATCC, Wesel, Germany) was cultured in 
Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum 
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(FBS) and 1% HAT Media Supplement (all Gibco, Life Technologies). Cell culture 
medium was supplemented with penicillin G sodium sulfate (100 units/ml), 
streptomycin sulfate (100 mg/ml), and amphotericin B (2.5 mg/ml) (all Gibco, Life 
Technologies).  
Macrophages J774.2 (#85011428, Sigma-Aldrich, Vienna, Austria;) were maintained 
in RPMI1640 medium with 10% FCS. 
Cells were sub-cultured using 0.025% trypsin/0.01% EDTA.  
 
HDL isolation  
HDL was isolated by a one-step density gradient ultracentrifugation method using 
long centrifuge tubes (16 x 76 mm; Beckman). Briefly, the density-adjusted serum 
(1.24 g/ml with KBr) was layered underneath a KBr-density solution (1.063 g/ml). 
Samples were centrifuged at 330,000 x g for 6 h (centrifuge: Beckman Optima L-80 
ultracentrifuge, rotor: Sorvall T-1270). Thereafter, the collected HDL was 
concentrated by Viva Spin Tubes (Sartorius, Vienna, Austria), desalted by gel 
filtration on Sephadex PD-10 columns (GE Healthcare, Munich, Germany) and used 
directly for compositional/functional analysis or stored at -80°C for the same purpose. 
 
Native gels  
Aliquots of HDL (10 µg) (without and with inhibitors) were electrophoresed on 4-15% 
non-denaturing polyacrylamide gels upon dilution with native sample buffer (Bio-Rad 
Laboratories, Vienna, Austria). The HiMark™ Pre-stained Protein Standard was used 
as standard for size determination. (Thermo Fischer Scientific, Germany). 
Electrophoresis was done in a running buffer (Invitrogen, Vienna, Austria) at 125V for 
4 h at room temperature. Gels were stained with Sudan black (Sigma-Aldrich, 
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Vienna, Austria) or were fixed with 10% sulfosalicylic acid for 30 min and then 
stained with Coomassie Brilliant Blue G250 (Sigma-Aldrich, Vienna, Austria). 
 
Western blots 
From HDL samples (without and with inhibitors), PON1-content was analyzed in 
aliquots of HDL (10 µg protein). The high molecular weight marker Native Mark (Life 
Technologies, Vienna, Austria) was used as standard. Samples were supplemented 
with 6 x loading buffers, boiled for 10 min and electrophoresed on 12% SDS-PAGE 
for 55 minutes at 175 V. Separated proteins were transferred to polyvinylidene 
difluoride (PVDF) membrane (Carl Roth, Karlsruhe, Germany) with blotting buffer 
(Tris, Glycine, EDTA, sodium azide) at 150 mA at 4°C for 90 min.  Membranes were 
blocked at RT in 10% powder milk for 1h followed by overnight incubation at 4°C with 
PON1 antibody (Abcam-ab24261, Cambridge, UK). 
After washing and incubation with appropriate secondary antibody (Dako, Vienna, 
Austria) protein signals were visualized by incubation with Millipore Western Blotting 
Substrate (Millipore Corporation, Billerica, USA) using ChemiDoc system (Bio-Rad 
Laboratories, Vienna, Austria). Expression levels PON1 of HDL samples (without or 
with inhibitors) were examined. Western blot signals were quantified using ImageJ 
(version 2006.02.01). Afterwards, signals were illustrated in Graph Pad Prism 
(version 5.0) as AUC under the signals.  
 
Kit measurement 
Commercially available kits for the determinations of total cholesterol (TC), 
triglycerides (TG) and phospholipids (PL) were purchased from Sigma Aldrich, 
Vienna, Austria). The amount of lipid component was normalized to 10 µg of protein 
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and quantitated by measuring the absorbance (490nm) on the Anthos microplate-
reader 2001 from Anthos Labtec Instruments GmbH (Salzburg, Austria) for each 
sample of HDL. 
 
PON1 (aryl esterase)-activity 
Ca2+-dependent aryl esterase activity of HDL-associated PON1 was determined with 
a photometric assay using phenyl acetate. Each HDL sample (1 µg protein) was 
added to 200 µl buffer containing 100 mmol/L Tris, 2 mmol/L CaCl2 (pH 8.0), and 1 
mmol/L phenyl acetate in a 96-well quartz glass plate (Hellma, Baden, Germany). 
The rate of hydrolysis of phenyl acetate was monitored by the increase of 
absorbance at 270 nm, and readings were taken every 15 seconds at room 
temperature to generate a kinetic plot. The slope from the kinetic chart was used to 
determine the increase in fluorescence per minute. Enzymatic (aryl esterase) activity 
was calculated with the Beer-Lambert Law from the molar extinction coefficient of 
1310 mol×L−1×cm−1 for phenyl acetate. 
 
eNOS-inducing activity measurement 
Intracellular conversion of L-[3H] arginine into L-[3H] citrulline was measured as a 
direct indicator of eNOS-inducing activity. Briefly, EA.hy926 cells grown in 6-well 
plates were washed and incubated at 37°C with 50 mM Tris buffer, pH 7.4, 
containing 100 mM NaCl, 5 mM KCl, 1 mM MgCl2, 3 mM CaCl2, 5% (vol/vol) FBS, L-
[2,3-3H]arginine (∼106 dpm) and 60 µM LPC 18:1 or PBS (vehicle). Reactions were 
terminated after 15 min by washing the cells with chilled Tris buffer (50 mM, pH 7.4), 
containing 100 mM NaCl, 5 mM KCl, 1 mM MgCl2 and 0.1 mM EGTA. After lysis of 
the cells with 0.01 N HCl, an aliquot was removed for determination of incorporated 
21 
 
radioactivity. To the remaining sample, 200 mM sodium acetate buffer (pH 13.0) 
containing 10 mM L-citrulline was added (final pH ∼5.0), and L-[3H] citrulline 
separated from L-[3H] arginine by cation exchange chromatography. 
 
Cholesterol efflux capacity measurement 
J774 macrophages plated on 48-well plates (300.000 cells/well) were labeled with 1 
μCi/mL [3H]-cholesterol (Perkin Elmer, Boston, MA, USA) for 24 hours. To upregulate 
ABCA1, the cells were stimulated with serum-free DMEM containing 0.3 mmol/L 8-(4-
chlorophenylthio)-cyclic AMP (Sigma, Darmstadt, Germany) for 6 hours. After 
labeling, the cells were washed and the [3H]-cholesterol efflux was determined by 
incubating the cells with 2.8% of HDL samples (2 µg HDL protein) for 4 hours. The 
cholesterol efflux was expressed as the radioactivity in the medium relative to total 
radioactivity in the medium and cells. All steps were performed in the presence of 2 
μg/mL of the acyl coenzyme A cholesterol acyltransferase inhibitor Sandoz 58-035 
(Sigma, Darmstadt, Germany). 
 
Inhibitors 
Torcetrapib and DTNB (5,5-dithio-bis-2-nitrobenzoic acid) were purchased from 
Sigma Aldrich (Vienna, Austria) and diluted in ethanol. The end concentrations of 
inhibitors were 10 µM and 2 mM, respectively  
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 Figure 3. Schematic view of the experiment. 
 
Pooled serum (with HDL) was kept on EL overexpressing HepG2 cells for 16 h. Afterwards, following 
12h incubation with CETP- or LCAT- overexpressing HepG2 cells without or with torcetrapib or DTNB, 
HDL was isolated from every condition yielding 6 different HDL samples. 
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4. Results 
 
 
Figure 4. Native gel Sudan Black staining of lipids. Samples are in duplicates without 
(left) and with (right) an inhibitor torcetrapib. 
CETP enhanced the intensity of Sudan staining of EV-HDL and EL-HDL both in the absence 
and presence of torcetrapib as compared to respective EV-controls (Fig. 4.). CETP and 
torcetrapib had no impact on size of either EV-HDL or EL-HDL (Fig. 5.). 
 
 
Figure 5. Native gel Coomassie staining of proteins. Samples are in duplicates 
without (left) and with (right) torcetrapib. 
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Figure 6. Native gel Sudan Black staining of lipids. Samples are in duplicates without 
(left) and with (right) an inhibitor DTNB. 
LCAT overexpression enhanced the intensity of EL-HDL Sudan staining (compared to 
EV2/EL-HDL) in the absence of DTNB (Fig. 6.). In the presence of DTNB the Sudan staining 
of LCAT/EL-HDL was weaker compared to EV2/EV1-HDL control (Fig. 6.). Neither LCAT nor 
DTNB affected size of EV-HDL or EL-HDL (Fig. 7.).   
 
 
 
Figure 7. Native gel Coomassie staining of proteins. Samples are without (left) and 
with (right) an inhibitor DTNB.  
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Figure 8. Western blots signals of PON1 without and with an inhibitor torcetrapib.  
EL-HDL samples showed decreased PON1-content. Torcetrapib (Fig. 8.) and DTNB (Fig. 9.) 
did not positively affect PON1-content of EL-HDL (yellow). *Line is separation for Western blots done 
separately.  
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Figure 9. Western blots signals of PON1 without and with an inhibitor DTNB.  
 *Line is separation for Western blots done separately. 
26 
 
    
Figure 10. Kit measurement of lipid composition (TC=total cholesterol, TG=triglycerides, 
PL=phospholipids) of samples without torcetrapib.  
EL-HDL samples showed increase in total cholesterol and decrease in triglycerides and 
phospholipids (Fig. 10.). EL-HDL modified with CETP overexpression (orange) had 
decreased total cholesterol (Fig. 10.). 
  
Figure 11. Kit measurement of lipid composition (TC=total cholesterol, TG=triglycerides, 
PL=phospholipids) of samples with torcetrapib (green, purple, blue and orange).  
Sample (EV2/EL; purple) had decreased total cholesterol, which was also visible in blue and 
orange samples. Sudan bands of CETP/EL with torcetrapib (Fig. 4.) were also less dark 
(sample CETP/EL), indicating lower cholesterol ester content. This suggests lower impact of 
torcetrapib on the composition of CETP/EL samples.  
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Figure 12. Kit measurement of lipid composition (TC=total cholesterol, TG=triglycerides, 
PL=phospholipids) of samples without DTNB.  
EL-HDL samples showed increased total cholesterol and decreased triglycerides and 
phospholipids. Decrease of total cholesterol was observed in EL-HDL following modification 
with LCAT (orange) (Fig.12.). 
 
 
 
Figure 13. Kit measurement of lipid composition (TC=total cholesterol, TG=triglycerides, 
PL=phospholipids) of samples with DTNB (green, purple, blue and orange).  
Sample (EV2/EL; purple) had decreased total cholesterol. Sample LCAT/EL (orange) had 
increased total cholesterol (Fig. 13.), accompanied by a less pronounced Sudan staining 
(Fig. 6.), suggesting higher content of free cholesterol and a significant impact of LCAT 
inhibition with DTNB.  
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Figure 14. PON1-activity of samples without and with torcetrapib. 
EL-HDL had decreased PON1-activity (Fig. 14.). Torcetrapib slightly lowered PON1-activity 
in CETP/EL sample (yellow). Decreased PON1-activity of EL-HDL was not improved with 
either torcetrapib (Fig. 14.) or DTNB (Fig. 15.). 
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Figure 15. PON1-activity of samples w thout and with DTNB.  
29 
 
EV
1 
po
ol
EL
 p
oo
l
EV
2/
E
V1
 p
oo
l
EV
2/
E
L 
po
ol
C
E
TP
/E
V1
 p
oo
l
C
E
TP
/E
L 
po
ol
EV
2/
E
V1
 p
oo
l +
TO
R
EV
2/
E
L 
po
ol
 +
 T
O
R
C
E
TP
/E
V1
 p
oo
l +
 T
O
R
C
E
TP
/E
L 
po
ol
 +
 T
O
R
0
10
20
30
40
50
eNOS activ ity of control and modified samples w ithout and
 w ith CETP inhibitor Torcetrapib
%
 c
o
n
v
e
rs
io
n
 o
f 
a
rg
in
in
e
 t
o
 c
it
ru
ll
in
e
 
Figure 16. eNOS-inducing activity of HDL p ep red in the absence or presence of 
torcetrapib.  
Compared to EV-HDL, EL-HDL exhibited increased capacity to induce eNOS-inducing 
activity in cultured endothelial cells. The eNOS-inducing capacity of both EV-HDL and EL-
HDL was increased with CETP and with torcetrapib (Fig. 16.). A combination of CETP and 
torcetrapib attenuated eNOS-inducing activity of EL-HDL but not of EV-HDL. (Fig. 16.). 
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Figure 17. eNOS-inducing activity HDL prepared in the absence or presence of 
DTNB.  
LCAT attenuated eNOS-inducing activity of EV-HDL and EL-HDL. DTNB only slightly 
affected eNOS-inducing capacity of EV-HDL and EL-HDL (Fig. 17.).  
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Figure 18. Cholesterol efflux capacity of samples without and with torcetrapib.  
Cholesterol efflux capacity of EL-HDL was significantly lower compared to EV-HDL (Fig. 18.). 
CETP, torcetrapib, LCAT and DTNB did not affect cholesterol efflux capacity of EV-HDL and 
EL-HDL (Fig. 18, 19.).  
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Figure 19. Cholesterol efflux capacity of samples without and with DTNB.  
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5. Discussion 
 
Native gels in all figures 4., 5., 6. and 7. showed that HDL modified by EL is smaller 
in size in the presence or absence of inhibitors (Torcetrapib and DTNB). In figure 7. 
there are significant shifts in bands when control samples are compared with EL-HDL 
samples. Control samples are always approx. between 12.5 and 8.2 nm, while EL-
HDL samples are approx. between 12 and 7.2 nm. Therefore, inhibitors do not 
modulate the total size of EL-HDL particles after CETP and LCAT overexpression.  
Sudan black staining (Fig. 4.) revealed that with torcetrapib, bands of samples were 
weaker when compared to those samples without inhibitor. When comparing bands 
from CETP/EV1 and CETP/EL (with torcetrapib), decrease in lipid content is more 
visible in the latter. Considering that Sudan has higher affinity for cholesterol esters 
(than free cholesterol) follows that torcetrapib had more effect on the control samples 
when compared to CETP-samples. Therefore, it seems that EL-HDL is less affected 
by CETP inhibition then control sample (CETP/EV1). 
Results in figure 5. showed an altered protein pattern in the sample CETP/EL with 
torcetrapib, especially around 7.2 nm (last two bands), possibly a consequence of 
torcetrapib-induced alterations in HDL-particle conformation. 
Results shown in figure 6. showed increased lipid content of cholesterol esters in 
LCAT/EV1 with DTNB, compared to LCAT/EL with DTNB suggests more pronounced 
inhibitory effect of DTNB on LCAT during acting on EL-HDL than on EV-HDL.  
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Furthermore, protein bands in figure 7. showed some protein conformation changes 
in the presence of DTNB.  
Lipid profile for CETP overexpression and inhibition, in figures 11. and 12., for 
samples of control HDL (sample EV1) and EL-HDL (sample EL) showed increase in 
total cholesterol and decrease in triglycerides and phospholipids for all EL modified 
samples. Only EL-HDL from CETP overexpression, without torcetrapib, had 
decreased total cholesterol (samples CETP/EV1 and CETP/EL in figure 10). Also, 
when torcetrapib was present in sample EV2/EL (Fig. 11.), decrease of total 
cholesterol was noticed. Sudan staining bands of CETP/EL with torcetrapib were also 
less prominent in figure 4 (sample CETP/EL), confirming that control sample was 
more prone for inhibition. Combining data from native gels and kit measurements, 
suggest a negligible effect of torcetrapib on the size and composition of CETP-
modified EL-HDL. 
Lipid profile for LCAT overexpression and inhibition, in figures 12., and 13., for 
samples of control HDL (EV1) and EL-HDL (sample EL) was similar as shown in 
figures 10. and 11; increased total cholesterol and decreased triglycerides and 
phospholipids were observed in all EL modified samples. Furthermore, EL-HDL 
modified with LCAT (LCAT/EL in Fig. 12.) had decreased total cholesterol when 
compared to control without inhibitor. This pattern also fits with Sudan gel in figure 6.                                      
In the presence of LCAT inhibitor the levels of total cholesterol were decreased in 
EV2/EL sample (Fig. 13.), but increased in EL-HDL from LCAT overexpressing 
HepG2 cells, likely due to inhibition of cholesterol esterification and accumulation of 
unesterified cholesterol in these particles (sample LCAT/EL in Fig. 13.). Sudan 
staining of those samples was somewhat different (Fig. 6., samples with inhibitors) 
with sample LCAT/EV1 having higher cholesterol ester content compared to 
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LCAT/EL which, as suggested above might be enriched with free unesterifeid 
cholesterol poorly detectable with Sudan staining. Combining data from native gels 
and kit measurements, it seems that DTNB affects more profoundly the impact of 
LCAT on the composition of EL- HDL, than EV-HDL  
In conclusion, EL-HDL particles were substrates for CETP and LCAT. Furthermore, 
structural and functional properties of EL-HDL were affected by both LCAT and 
CETP. While torcetrapib more profoundly affected CETP-modification of EV-HDL 
compared to EL-HDL, situation was opposite with DTNB, which more profoundly 
affected LCAT-modification of EL-HDL compared to EV-HDL. 
PON1-content was decreased in EL-modified HDL. PON1-content did not change in 
the presence of torcetrapib or DTNB presence. In conclusion, both inhibitors did not 
show any positive effect regarding PON1-content of EL-HDL. 
PON1-activity was decreased in EL-HDL. Torcetrapib slightly lowered PON1-activity 
in CETP/EL-HDL. DTNB effect on PON1-activity followed the same pattern. 
In figures 16. and 17., eNOS-inducing activity was higher in cells treated with EL-
HDL without inhibitors. EL-HDL modified with CETP in the presence of, torcetrapib 
exhibited decreased eNOS-inducing activity, compared to CETP/EV1 HDL sample. 
Hence, torcetrapib negatively affects only eNOS-inducing activity of EL-HDL modified 
by CETP, while in other particles from EL pool eNOS-inducing activity remains 
higher, compared with control HDLs. 
DTNB effects on eNOS-inducing activity of HDL activity were insignificant. 
Cholesterol efflux capacity of EL-HDL was decreased regardless of inhibitors or 
CETP or LCAT overexpression (Fig. 18 and 19). 
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6. Conclusion 
 
EL-HDL is suitable substrate for CETP and LCAT. Overexpression of CETP and 
LCAT altered lipid composition without affecting size of EL-HDL Pharmacological 
modulation showed that inhibitors, torcetrapib and DTNB are able to affect lipid 
composition of EL-HDL.  
- Torcetrapib has more pronounced effect on EL-HDL without additional CETP 
modification, while DTNB effects on EL-HDL are dependent on LCAT 
overexpression. 
 
PON1-content, PON1-activity and cholesterol efflux capacity are decreased in all EL-
HDL samples, regardless of CETP, or LCAT, overexpression and inhibition. In 
contrast, eNOS-inducing activity of all EL-HDL samples, except those with 
torcetrapib, were higher when compared to control HDL.  
 
In conclusion, composition but not functionality of EL-HDL is affected by CETP and 
LCAT. When inhibitors, torcetrapib and DTNB, are present - result is the same. In 
vitro pharmacological inhibition of CETP and LCAT, failed to affect their impact on 
the functionality of the EL-HDL. 
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